IMmotion trials: CSF-1R inhibitors in NSCLC had poor monotherapy activity but enhanced response with ICIs; TGF-β blocker + anti-PD-L1 in RCC showed increased CD8+ T cell infiltration (NCT02452424). This evidence concerns the gene TGFB1 and renal cell carcinoma.